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The NLRP3 inflammasome is activated by
nanoparticles through ATP, ADP and adenosine
L Baron1, A Gombault1, M Fanny1, B Villeret1, F Savigny1, N Guillou1, C Panek1, M Le Bert1, V Lagente2, F Rassendren3, N Riteau1
and I Couillin1
The NLR pyrin domain containing 3 (NLRP3) inflammasome is a major component of the innate immune system, but its mechanism
of activation by a wide range of molecules remains largely unknown. Widely used nano-sized inorganic metal oxides such as silica
dioxide (nano-SiO2) and titanium dioxide (nano-TiO2) activate the NLRP3 inflammasome in macrophages similarly to silica or
asbestos micro-sized particles. By investigating towards the molecular mechanisms of inflammasome activation in response to
nanoparticles, we show here that active adenosine triphosphate (ATP) release and subsequent ATP, adenosine diphosphate (ADP)
and adenosine receptor signalling are required for inflammasome activation. Nano-SiO2 or nano-TiO2 caused a significant increase
in P2Y1, P2Y2, A2A and/or A2B receptor expression, whereas the P2X7 receptor was downregulated. Interestingly, IL-1β secretion in
response to nanoparticles is increased by enhanced ATP and ADP hydrolysis, whereas it is decreased by adenosine degradation
or selective A2A or A2B receptor inhibition. Downstream of these receptors, our results show that nanoparticles activate the NLRP3
inflammasome via activation of PLC-InsP3 and/or inhibition of adenylate cyclase (ADCY)-cAMP pathways. Finally, a high dose of
adenosine triggers inflammasome activation and IL-1β secretion through adenosine cellular uptake by nucleotide transporters and
by its subsequent transformation in ATP by adenosine kinase. In summary, we show for the first time that extracellular adenosine
activates the NLRP3 inflammasome by twoways: by interacting with adenosine receptors at nanomolar/micromolar concentrations
and through cellular uptake by equilibrative nucleoside transporters at millimolar concentrations. These findings provide new
molecular insights on the mechanisms of NLRP3 inflammasome activation and new therapeutic strategies to control inflammation.
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The inflammasome is a major factor of the innate immune
system acting as amultiprotein platform to activate caspase-1.
We showed recently that nanoparticles of TiO2 (nano-TiO2)
and SiO2 (nano-SiO2) are sensed by the NLRP3 inflamma-
some to induce the release of mature IL-1β,1 as observed
previously with the environmental irritants asbestos or silica.2
Despite the identification and characterisation of numerous
sterile or microbial activators, the precise mechanisms
mediating NLRP3 inflammasome activation remain to be
determined. Here, we investigated whether ATP release and
purinergic signalling through ATP, ADP and adenosine may be
involved in inflammasome activation by nanoparticles.
Intracellular ATP is released after cellular stress and/or
activation, and purinergic signalling has been shown to
modulate inflammation and immunity.3,4 In the extracellular
space, ATP is rapidly hydrolysed in a stepwise manner to
ADP, AMP (adenosine monophosphate) and adenosine by
ectoenzymes.4 Adenosine is then irreversibly hydrolysed to
inosine by adenosine deaminase (ADA). Extracellular ATP
(eATP) signals through both ATP-gated ion channels P2X and
G protein-coupled receptor (GPCR) P2Y membrane recep-
tors, whereas ADP signals through P2Y receptors and
adenosine through P1 receptors (or A receptors).5 P2Y
receptors and A receptors may be coupled to the Gq protein,
which activates phospholipase C-beta (PLC-β), to the
stimulatory G (Gs) protein, which stimulates adenylate cyclase
inducing an increase in cyclic AMP (cAMP) levels, or to the G
inhibitory (Gi) protein, which inhibits adenylate cyclase.
Extracellular adenosine level is the result of adenosine
production from extracellular ATP and ADP, its degradation
into inosine and its reuptake by cells. Both ATPand adenosine
can be transported outside of the cell via diffusion or active
transport, whereas only adenosine can enter the cells through
adenosine transporters.6 Most cells possess equilibrative and
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concentrative adenosine transporters (respectively, ENTs and
CNTs), which allow adenosine to quickly cross the plasma
membrane.7 Intracellular adenosine is converted to ATP via
phosphorylation steps mediated by adenosine kinase (AK)
and AMP kinase (AMPK). The basal physiological level of
extracellular adenosine has been estimated to be in the range
of 30–200 nM.8 ATP-derived adenosine and its subsequent
signalling through P1 receptors have beneficial roles in acute
disease states.4,9 However, during tissue injury, elevated
adenosine levels participate in the progression to chronic
diseases by promoting aberrant wound healing leading to
fibrosis in different organs including the lungs, liver, skin and
kidney. In these conditions the blockade of adenosine signalling
is beneficial.10–16 In murine models, ADA-knockout mice
present high persistent adenosine levels, which lead to
airspace enlargement and fibrosis, cardinal signs of COPD
and IPF.14,17,18
Here we investigate in more detail the critical contribution of
purinergic signalling in driving NLRP3 inflammasome activa-
tion in response to nanoparticles pointing out the effect of ATP,
ADP, as well as adenosine and its receptors. We also identify
ATP-derived adenosine as a potential activator of the
inflammasome.
Results
Nano-SiO2 or nano-TiO2 particles trigger active ATP
release and IL-1β secretion through purinergic signalling
and pannexin/connexin hemichannel activity. We
recently showed that nano-SiO2 and nano-TiO2, but not
nano-ZnO, activate the NLRP3 inflammasome in human and
murine macrophages.1 Here we studied whether active ATP
release, purinergic signalling and connexin/pannexin channel
activity are involved in inflammasome activation by nano-SiO2
and nano-TiO2. Using the ecto-ATPase inhibitor ARL67156 to
limit ATP catabolism,19 we observed that nano-SiO2
(Figure 1a) or nano-TiO2 (Figure 1b), but not nano-ZnO
(Figure 1c), causes an active release of endogenous ATP in
primed THP1 macrophages, which peaks at 3–4 h and just
precedes mature IL-1β secretion. Importantly, nano-TiO2,
nano-SiO2 or nano-ZnO did not induce necrosis or apoptosis
even after 6 h of stimulation (Figures 1d and e). We confirmed
the importance of the inflammasome in IL-1β production in
response to nanoparticles using THP1 cells stably expres-
sing short hairpin ribonucleic acid (shRNA) against compo-
nents of the inflammasome, the NLRP3 protein itself or the
adaptor protein apoptosis-associated speck-like protein con-
taining a CARD domain (ASC) (Figure 1f). By investigating
the mechanisms of nanoparticle-induced ATP release leading
to IL-1β secretion, we observed that specific inhibition of the
P2X7 receptor (P2X7R) by A740003 at 10 μM led to partial
inhibition of ATP release and IL-1β secretion by nano-SiO2
and nano-TiO2 (Figures 1g and h). Among several potential
mechanisms of nucleotide release, we focused on the
connexin and pannexin families, which are able to form
hemichannels.20,21 The connexin/pannexin channel blockers
carbenoxolone (Cbx) and flufenamic acid (FFA) significantly
reduced both ATP and IL-1β releases (Figures 1g and h).
Although unable to induce IL-1β by themselves, the addition
of the nucleotides ATP or ADP or their stable derivatives
ATPγS or ADPβS greatly increased IL-1β production by
THP1 cells in response to nanoparticles (Figure 1i). Unlike
what we observed with THP1 human monocyte/macrophage
cell line, we were unable to measure significant ATP increase
in the supernatant of stimulated murine bone-marrow-derived
macrophages (BMDMs). This might probably be owing to the
fastest ATP degradation by these cells as proposed.22
However, the use of two different P2R antagonists, suramin
and periodate-oxidised ATP (oATP), dose-dependently led to
the reduction of IL-1β production induced by nano-SiO2 or
nano-TiO2 (Figure 2a). Cbx and FFA also induced the
reduction of IL-1β release (Figure 2b). Western blotting
analysis confirmed that nano-SiO2 or nano-TiO2 triggers the
cleavage of pro-IL-1β into the mature 17 kDa IL-1β form and
its secretion in primed BMDMs. The addition of oATP,
A740003, Cbx or FFA strongly reduced the secretion of
mature IL-1β (Figure 2c). Similarly, the cleavage of pro-
caspase-1 into the secreted mature p10 subunit was reduced
in the presence of oATP, Cbx or FFA (Figure 2d), confirming
that NLRP3 inflammasome activation depends on purinergic
signalling and connexin/pannexin channels.
Nanoparticles induce IL-1β secretion through metabo-
tropic P2Y receptor signalling. To identify more precisely
the purinergic receptors involved, we performed quantitative
mRNA expression analysis of P2 purinergic receptors. P2Y2
receptor (for ATP/UTP) mRNA level was increased after
nano-SiO2 or nano-TiO2 particle stimulation, whereas P2Y1
receptor (ADP) mRNA level was increased only after nano-
SiO2 stimulation (Figure 3a). In contrast, mRNA levels of
P2Y7 (ATP), P2Y4 (UTP), P2Y6 (UDP) or P2Y12 (ADP)
receptors were slightly reduced after nano-SiO2 stimulation
(Figure 3a) and also P2Y12 receptor after nano-TiO2
stimulation. Deficiency in the ATP ionotropic P2X7 or P2X4
did not lead to significant impairment in IL-1β production by
BMDMs upon nanoparticle stimulation (Figure 3b). Defi-
ciency in the ATP/UTP metabotropic P2Y2 receptor, notably
involved in cell chemotaxis in response to ATP leakage,23
promoted a slight decrease in IL-1β production (Figure 3c). In
addition, we found that P2Y1 receptor antagonist MRS2500
(Figure 3d) decreased nano-SiO2- but not nano-TiO2-induced
mature IL-1β secretion, whereas P2Y6 receptor (UDP)
antagonist MRS2578 (Figure 3e) and P2Y12 receptor
(ADP) antagonist MRS2395 (Figure 3f) had no effect on
nanoparticle-induced IL-1β secretion. Altogether, these
results suggest that P2Y1 (ADP) and P2Y2 (ATP/UTP)
receptors are involved in the activation of the NLRP3
inflammasome by nano-SiO2.
Nanoparticles induce mature IL-1β secretion through
adenosine and P1 receptors signalling. We stimulated
murine macrophages in the presence of the ATP-consuming
enzyme apyrase grade VII, which hydrolyses ATP and ADP
into AMP. Apyrase did not abrogate IL-1β secretion induced
by nano-TiO2 or nano-SiO2 but, on the contrary, slightly
increased it (Figure 4a). Then, in the presence of the
adenosine deaminase (ADA), IL-1β secretion by nano-SiO2
or nano-TiO2 was greatly reduced (Figure 4b). Similarly, we
stimulated THP1 cells with nano-SiO2, in the presence of
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Figure 1 Nano-SiO2 or nano-TiO2 particles trigger active ATP release and IL-1β secretion through purinergic signalling and pannexin/connexin hemichannel activity. Nano-SiO2
(a) or nano-TiO2 (b) triggered active release of ATP in the supernatant by PMA-primed THP1 that peaks between 3 and 4 h. This ATP release was correlated with a secretion of IL-1β
(a,b). Nano-ZnO did not induce ATP release or IL-1β secretion (c). Apoptotic (PI− anV+) and necrotic (PI+ anV− ) cell death of primed THP1 was monitored using the AnnexinV/PI
staining (d,e). ARL67156 (50 μM) was added to the supernatant during stimulation to limit ATP catabolism (a–c). IL-1β secretion by nano-SiO2 or nano-TiO2 was attenuated in
THP1 cells stably expressing shRNA directed against ASC (sh ASC) or NLRP3 (sh NLRP3) in comparison with THP1 transfected with lamin-specific shRNA (sh CTL) (f). Nano-ZnO
did not induce IL-1β secretion after 4 h of stimulation (f). Specific inhibition of P2X7R by A740003 partially decreased ATP release and IL-1β secretion by PMA-primed THP1 after 4 h
nanoparticle stimulation (g,h). Connexin/pannexin channel blocker carbenoxolone (Cbx) and connexin channel blocker flufenamic acid (FFA) reduced both ATP release and IL-1β
secretion upon nano-SiO2 or nano-TiO2 (g,h). PMA-primed THP1 stimulated for 4 h with 200 μM ATP, ADP or their stable derivatives ATPγS or ADPβS greatly increased IL-1β
production in response to nanoparticles, whereas these nucleotides had no effect alone (i). Nanoparticles are at the concentration of 250 μg/ml (a–h) or 125 μg/ml (i). Data are
representative of 2–4 independent experiments. Data are mean±S.D. of triplicates, compared between untreated and nanoparticle-stimulated THP1; ααα, P≤ 0.001 for THP1, βββ,
P≤ 0.001 for THP1 sh CTL, γγγ, P≤ 0.001 for THP1 sh ASC, δδδ: P≤ 0.001 for THP1 sh NLRP3 (f). Data are mean± S.D. of triplicates, compared between nanoparticle-
stimulated THP1 and nanoparticles plus inhibitor or agonist; *** and ααα, P≤ 0.001 for nano-SiO2 and nano-TiO2 stimulated THP1, respectively (g–i)
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Figure 2 Nano-SiO2- or nano-TiO2-induced IL-1β in mouse macrophages is dependent on purinergic signalling. IL-1β production by LPS-primed BMDMs stimulated for 6 h
with nano-SiO2 or nano-TiO2 was dose dependently decreased by P2R antagonists suramin (200, 400 or 600 μM) and oATP (100, 200 or 400 μM) (a). Cbx (50 or 100 μM) and
FFA (25, 100 or 250 μM) significantly reduced IL-1β release by murine macrophages (b). Western blotting analysis of LPS-primed BMDM supernatants (SN) confirmed that FFA
(100 μM), Cbx (50 μM) oATP (200 μM) or A740003 (100 μM) strongly reduced the secretion of the mature 17kD IL-1β form mIL-1β in response to nano-SiO2 or nano-TiO2 (c).
Similarly FFA, Cbx or oATP significantly reduced autoproteolytic cleavage of the pro-caspase-1 into the secreted p10 subunit (d). Stimulation of BMDMs with ATP (5 mM, 45 min)
induced mature IL-1β (c) and caspase-1 (d) releases in the supernatant, whereas nano-ZnO did not induce these cleavages (c,d). BMDM extracts (XT) prepared from the same
experiments were blotted with anti-β-actin, anti-pro-IL-1β and anti-pro-caspase-1 for control (c,d). Molecular-weight markers are shown at the right (c,d). BMDMswere stimulated
with 250 μg/ml nanoparticles during 6 h. Data are representative of three independent experiments. Data are mean± S.D. of triplicates, compared between nanoparticle-
stimulated THP1 and nanoparticles plus inhibitor; *** and ααα, P≤ 0.001 for nano-SiO2 and nano-TiO2 stimulated THP1, respectively (a,b)
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apyrase or ADA. Measurement of eATP levels showed that,
even when ATP was degraded by apyrase, IL-1β secretion
was still observed and even slightly increased (Figure 4c).
When ADA was added to the nanoparticles, we noted a
potent decrease in IL-1β and ATP levels probably owing to a
shift in the balance of the ATP/ADP towards adenosine
(Figure 4d). Next, the addition of the non-degradable pan-
adenosine receptor agonist 5'-N-Ethylcarboxamidoadenosine
(NECA; 0.3–30 μM) significantly increased nano-SiO2-
but not nano-TiO2-induced IL-1β secretion (Figure 4e).
In contrast, adenosine had no effect at these concentrations,
but only increase IL-1β at higher concentrations
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Figure 3 Nanoparticles induce IL-1β secretion through P2Y metabotropic purinergic receptors in murine macrophages. Expression of P2X7, P2Y1, P2Y2, P2Y4, P2Y6,
P2Y12 and P2Y13 receptors in LPS-primed BMDMs stimulated for 4 h with nano-SiO2 or nano-TiO2 (250 μg/ml) was analysed by quantitative PCR (a). P2Y1 (for nano-SiO2 only)
and P2Y2 mRNA levels were increased, whereas P2X7, P2Y4, P2Y6, P2Y12 and P2Y13 mRNA levels were slightly reduced 4 h after nano-SiO2 or nano-TiO2 stimulation (a).
Macrophages from wild-type (B6), P2X7-, P2X4- or P2Y2-deficient mice were stimulated with nanoparticles. P2X4 and P2X7 deficiency had no effect (b), whereas P2Y2
deficiency slightly decreased IL-1β secretion (c). IL-1β production by LPS-primed BMDMs was slightly decreased with the P2Y1 inhibitor MRS2500 (d), whereas no effect was
observed with the P2Y6 inhibitor MRS2578 (e) and P2Y12 inhibitor MRS2395 (f) upon nanoparticle (250 μg/ml) stimulation (Data are representative of three independent
experiments *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ns: not statistically different)
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(100–300mM) probably because adenosine is rapidly
degraded into inosine by ADA (not shown). In addition,
IL-1β induced by nano-SiO2 but not by nano-TiO2 was slightly
decreased in the presence of the CD73 inhibitor AMP-CP,
suggesting that adenosine is more important for nano-SiO2-
induced IL-1β (Figure 4f). These results indicate that
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Figure 4 Nanoparticles induce mature IL-1β secretion through adenosine and P1 receptor signalling. LPS-primed murine BMDMs were stimulated for 6 h with nano-SiO2 or
nano-TiO2 in the presence of increasing concentrations of apyrase grade VII (0.3, 1, 3 or 10 U/ml) (a). Nano-SiO2- and nano-TiO2-induced IL-1β were slightly decreased and then
rapidly increased (a). LPS-primed BMDMs were also stimulated for 6 h with nano-SiO2 or nano-TiO2 in the presence of increasing doses of ADA (0.3, 1, 3 and 10 U/ml) (b).
Apyrase grade VII or ADA alone had no effect on IL-1β secretion by murine macrophages (a,b). PMA-primed THP1 were stimulated for 6 h with nano-SiO2 (250 μg/ml) in the
presence of different concentrations of apyrase VII (c) or ADA (d). Nano-SiO2-induced eATP decreased by increasing apyrase VII, whereas IL-1β remained elevated (c). ADA
dose dependently decreased both nano-SiO2-induced IL-1β and eATP secretions (d). Apyrase VII or ADA alone had no effect on IL-1β and eATP secretions by human
macrophages (c,d). LPS-primed murine BMDMs were stimulated for 6 h with nano-SiO2 or nano-TiO2 in the presence of increasing concentrations of NECA (e) or AMP-CP (f).
IL-1β secretion induced by nanoparticles was increased in the presence of NECA (e) and remained stable in the presence of AMP-CP (f). Data are representative of three
independent experiments (*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ns: not statistically different)
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adenosine generated after nanoparticle-induced ATP release
participates with ATP and ADP in promoting inflammation and
NLRP3 inflammasome activation.
A2A, A2B and A3 receptors are involved in NLRP3
inflammasome activation. P1 purinergic receptors mRNA
expression showed that both A2A and A2B mRNAs are
increased in the presence of nano-SiO2 or nano- TiO2,
whereas A3 and A1 mRNA expression levels did not
significantly change (Figure 5a). Moreover, we showed
that the specific A2A (SCH58261), A2B (MRS1754) or the
specific A3 (MRS1523) inhibitors decreased IL-1β secretion
after nano-SiO2 or nano-TiO2 stimulation (Figures 5b–d).
In contrast, the specific antagonist of A1 receptor (DPCPX)
had no effect on IL-1β secretion (Figure 5e). These results
identified adenosine as a crucial mediator of IL-1β secretion
through the high-affinity A2A receptor and the low-affinity A2B
and A3 receptors in response to nanoparticle activation in
murine macrophages.
Nanoparticles trigger NLRP3 inflammasome through the
activation of PLC-InsP3 and inhibition of ADCY-cAMP
pathways. We investigated pathways leading to inflamma-
some activation downstream of purinergic receptors. Both
P2Y and P1 receptors belong to the GPCR family acting
through numerous signalling cascades and have been linked
to inflammation.24 P2Y1, P2Y2, A3 and A2B receptors
involved in nanoparticle-mediated inflammasome activation
can be coupled to the heterotrimeric G proteins of the Gq
family that activate phospholipase C-β (PLC-β). We show that
the inhibitor of PLC-β, U73122, blocked nanoparticle-induced
IL-1β secretion (Figure 6a). PLC-β is able to hydrolyse
phosphatidylinositol-4, 5-bisphosphate into diacylglycerol
(DAG), activating the protein kinase C and the production of
the inositol trisphosphate (InsP3), which in turn causes an
increase in cytosolic Ca2+ by binding to InsP3 receptors
located in the endoplasmic reticulum. As intracellular Ca2+
(iCa2) increase was shown to directly activate the NLRP3
inflammasome,25 we analysed the effect of 2-APB, a
molecule chelating and hence blocking the increase of iCa2+.
We observed that 2-APB strongly reduced nanoparticle-
induced IL-1β secretion (Figure 6b). Moreover, adenosine
receptors can also be coupled to the Gs family activating
ADCY or the Gi/o family inhibiting ADCY with subsequent
augmentation or reduction of cyclic AMP (cAMP). As cAMP
was shown to bind and suppress NLRP3 inflammasome
activation directly,25 we examined the involvement of ADCY in
nanoparticle-induced IL-1β secretion. The addition of the
ADCY activator forskolin dose dependently inhibited
nanoparticle-induced IL-1β secretion (Figure 6c), whereas
the addition of the ADCY inhibitor SQ22536 had no effect
(Figure 6d). Collectively, these results indicate that
nanoparticles trigger the NLRP3 inflammasome pleonasm
through both activation of PLC-InsP3 and inhibition of ADCY-
cAMP pathways.
Adenosine induces IL-1β secretion and ATP release in
THP1 human macrophages. We observed that high con-
centrations of adenosine (100 μM), which does not corre-
spond to adenosine receptor affinities, enhanced ATP
release and IL-1β secretion on nanoparticles in THP1
macrophages (Figure 7a). Moreover, adenosine at 5 mM
was alone able to trigger ATP release and IL-1β secretion,
whereas 100 μM adenosine had no effect (Figure 7a). IL-1β
secretion induced by nanoparticles plus adenosine (5 mM) or
adenosine alone in the presence of the specific caspase-1
inhibitor Z-YVAD-fmk was greatly reduced (Figure 7c). More-
over, IL-1β secretion in response to a high dose of adenosine
was not induced in THP1-expressing shNLRP3 or shASC
(Figure 7d). Intracellular and extracellular adenosine levels
are regulated by equilibrative nucleoside transporters (ENTs)
present at the cell membrane.7 Cellular adenosine uptake
may lead to intracellular metabolism of adenosine in ATP by
adenosine kinase and subsequent release of ATP and IL-1β
secretion.6 To test these possibilities, we stimulated THP1
macrophages with increasing doses of adenosine, NECA, the
non-degradable analogue of adenosine or inosine, the
metabolite of adenosine degradation by ADA. We observed
that even if high doses of adenosine triggered ATP release
and IL-1β secretion, the same doses of NECA had no effect,
demonstrating that metabolism of adenosine is necessary for
these responses (Figure 7e). One possibility for adenosine to
be metabolised is its hydrolysis in inosine by ADA. Never-
theless, high doses of inosine were unable to promote eATP
and IL-1β release (Figure 7e). Millimolar doses of adenosine,
NECA or inosine did not induce cell death (Figure 7e). The
other possibility is an adenosine reuptake through ENTs and
intracellular metabolism of adenosine in ATP by adenosine
kinase. To test this hypothesis, we measured eATP and IL-1β
induced by millimolar concentrations of adenosine in the
presence of 5-iodotubercidin, a pharmacological inhibitor of
both adenosine kinase and ENTs, and showed that eATP and
IL-1β release was reduced (Figure 7f). We used NBMPR, a
pharmacological inhibitor of ENTs that is specific for ENT1
(Ki=0.4 nM) and ENT2 (ki=2.8 μM) at nM and μM concen-
trations, respectively. We observed that NBMPR inhibited
eATP and IL-1β only at μM doses (Figure 7g). The mRNA
expression of ENT2 was significantly increased by millimolar
concentrations of adenosine (Figure 7h). Millimolar concen-
trations of adenosine significantly increased NLRP3 mRNA
expression, supporting the role of adenosine in NLRP3
inflammasome activation (Figure 7i). In addition, intracellular
ATP contents were increased after addition of extracellular
adenosine at high doses (Figure 7j). Altogether, these results
indicate that extracellular adenosine when present at a high
concentration is recaptured by macrophages through ENT2
transporters and metabolised in ATP by adenosine kinase
leading to ATP release and NLRP3 inflammasome activation.
Early nanoparticle-induced pulmonary inflammation
depends on adenosine. Airway exposure to ultrafine
particles is associated with strong infiltration of neutrophils
in the airways in humans and mice.1,26 We instilled mice with
nano-TiO2 or nano-SiO2 and visualised the presence of
nanoparticle aggregates in lung parenchyma at 24 h
(Figure 8a). Similarly to nano-TiO2,
1 nano-SiO2 elicited a
considerable neutrophil influx in the BALF at 6 h (Figure 8b),
which correlated with the production of the neutrophil
chemoattractant KC (Figure 8c) and the metalloproteinase-9
(MMP-9) present in neutrophil β2 gelatinase granules
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(Figure 8d). Moreover, myeloperoxidase (MPO) present in
neutrophils α azurophilic granules (Figure 8e) and IL-1β
levels (Figure 8f) were also increased in lung homogenates.
As we observed that nano-SiO2 instillation induced a
transient increase of ATP content locally and that ATP is
rapidly degraded, adenosine can act as a danger signal
involved in lung inflammation. We performed local adenosine
depletion experiments in mice by using ADA, which catalyses
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Figure 5 A2A, A2B and A3 receptors were involved in NLRP3 inflammasome activation. Quantitative PCR analysis of P1 receptor expression in LPS-primed BMDMs
stimulated for 4 h with nano-SiO2 or nano-TiO2. A2A and A2B mRNA levels were greatly increased by nanoparticles, whereas A3 mRNAwas slightly increased only by nano-TiO2,
and A1 expression remained unchanged (a). The specific A2A (SCH58261), A2B (MRS1754) and A3 (MRS1523) inhibitors dose dependently decreased IL-1β production by LPS-
primed BMDMs, whereas specific A1 inhibitor (DPCPX) had no inhibitory effect on IL-1β secretion (b-e). Inhibitor concentrations were 0.1, 0.3, 1, 3 and 10 μM for DPCPX and
SCH58261, and 0.3, 1, 3, 10 and 30 μM for MRS1754 and MRS1523; inhibitors alone did not induce IL-1β production after 6 h (b–e). Nanoparticles were used at 200–250 and
300 μg/ml for nano-SiO2 and nano-TiO2, respectively. Data are representatives of 2–4 independent experiments (*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ns: not statistically different)
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the conversion of adenosine into inosine. We observed that
local treatment with ADA reduced nano-SiO2-induced acute
inflammation, resulting in markedly reduced neutrophils
(Figure 8b), KC (Figure 8c), MMP-9 (Figure 8d) contents in
BALF and attenuated MPO (Figure 8e) and IL-1β levels
(Figure 8f) in the lung. These data indicate that adenosine
generated in vivo after nanoparticle-induced lung injury has
an early pro-inflammatory role, as observed in vitro for
macrophages.
Discussion
Despite extensive studies, the mechanisms of NLRP3
inflammasome activation are not well understood. Here we
demonstrate that SiO2 and TiO2 nanoparticles promote the
secretion of mature IL-1β by macrophages through the active
release of ATP in the extracellular space. Interestingly,
ATP but also its degrading products ADP and adenosine
are important signalling molecules that allow NLRP3
inflammasome activation and mature IL-1β secretion in
macrophages.
We showed that nano-SiO2 and nano-TiO2, but not nano-
ZnO, induced the active release of ATP through connexin
and/or pannexin hemichannels leading to IL-1β secretion by
macrophages. ATP release and IL-1β secretion depend on
purinergic signalling and in particular on the P2X7R for ATP,
contrarily to IL-1β secretion. The addition of nucleotides such
as ATP or ADP, or their stable derivatives ATPγS or ADPβS,
greatly increased IL-1β production by macrophages, indicat-
ing that ATP and ADP are involved in nanoparticle-mediated
NLRP3 inflammasome activation. Importantly, nano-SiO2 and/
or nano-TiO2 increased the mRNA expression of P2Y1 and/or
P2Y2, whereas P2Y4, P2Y6, P2Y12 and/or P2X7 receptor
mRNAs were downregulated in primed murine macrophages.
When CD39, which degrades extracellular ATP into ADP and
AMP, was inhibited in THP1 cells using ARL67156, eATP and
IL-1β levels were increased. One can hypothesise that it
favours IL-1β secretion through the ATP-specific P2Y2
receptor. On the contrary, in the presence of adenosine
deaminase (ADA), IL-1β was greatly but not totally reduced,
pointing out an additional important role for adenosine as a
major ATP-derived signalling nucleoside promoting IL-1β
secretion after nano-SiO2 or nano-SiO2 macrophage activa-
tion. Importantly, nano-SiO2 and/or nano-TiO2 increased
mRNA expression levels of A2A, A2B and slightly of A3
receptors, but not of A1 receptors. In addition, specific A2A and
A2B inhibitors decreased IL-1β secretion, confirming that
adenosine is a crucial mediator of IL-1β secretion essentially
through the high-affinity A2A and the low-affinity A2B adeno-
sine receptors in response to nanoparticle activation in
macrophages. In THP1 cells, adenosine degradation by
ADA leads to a decrease of eATP, potentially due to the deficit
of conversion of ADP/ATP from adenosine because of the
increased degradation of adenosine to inosine. This reduction
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Figure 6 Nanoparticles trigger NLRP3 inflammasome through activation of PLC-InsP3 and inhibition of ADCY-cAMP pathways. LPS-primed murine BMDMs were stimulated
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in ATP, ADP and adenosine allowed greatly reducing IL-1β
secretion probably through signalling by P2Y2, P2Y1, A2A,
A2B and A3 receptors. Downstream of purinergic receptors,
which are coupled to G proteins (GPCR), we propose that
nanoparticles trigger maturation of IL-1β through activation of
PLC-β/InsP3 and inhibition of ADCY-cAMP pathways. This
suggests that intracellular Ca2+ increase and cAMP
decrease are second signals required for NLRP3 inflamma-
some by the nano-SiO2 and nano-TiO2. It was shown recently
that activation of another GPCR, the calcium-sensing
receptor, by CaCl2 signals through similar pathways.
25
In addition, we report that NECA, the non-degradable
pan-adenosine receptor agonist, potentiated nanoparticle-
induced IL-1β secretion, strengthening the role of adenosine
as an essential danger signal in NLRP3 inflammasome
triggering. Our work demonstrates that adenosine, as well
as ATP or ADP, participates in inflammasome activation via
multiple receptor signalling pathways.
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Figure 7 Adenosine induces IL-1β secretion and ATP release in THP1 human macrophages. PMA-primed THP1 cells were stimulated during 6 h with 250 μg/ml nano-SiO2,
500 μg/ml nano-TiO2 and/or high concentrations of adenosine (Ado), and eATP and IL-1β releases were measured. Adenosine potentiated eATP release and IL-1β secretion
upon nanoparticle stimulation without inducing change in cell viability (a). High doses of adenosine alone induced IL-1β secretion by PMA-primed THP1 in a dose-dependent
manner (b). The caspase-1-specific inhibitor Z-YVAD-fmk (5 μM) remarkably reduced adenosine- and/or nanoparticle-induced IL-1β secretion; Z-YVAD-fmk alone had no effect
(c). Adenosine-dependent induction of IL-1β secretion was reduced in THP1 sh NLRP3 or THP1 sh ASC but not in unmodified THP1 or THP1 sh CTL (d). PMA-primed THP1
cells were stimulated with increasing doses of adenosine, the non-metabolisable analogue of adenosine NECA or inosine (Ino), the product of adenosine hydrolysis by ADA, and
cell supernatants were analyzed to measure eATP, IL-1β and cell death (e). PMA-primed THP1 cells were stimulated with mM doses of adenosine in the presence of 5-
iodotubercidin (5-Iodo), an inhibitor of both adenosine kinase and ENTs, or in the presence of NBMPR, an inhibitor of ENT1 at nM doses and ENT2 at μM concentrations, and
eATP and IL-1β releases were measured at 6 h (f,g). Quantitative PCR analysis of ENT1, ENT2 and NLRP3 expression in PMA-primed THP1 stimulated for 6 h with increasing
concentrations of Ado was performed (h,i). Intracellular ATP contents were measured 6 h after stimulation with high concentrations of adenosine (j). Data are representative of 2–
3 independent experiments (*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ns: not statistically different)
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As extracellular ATP is degraded in adenosine within
minutes, it is more likely that adenosine participates in early
steps of NLRP3 inflammation activation rather than in
sustained inflammasome activation, as suggested recently.27
Extracellular adenosine is finely regulated by adenosine
degradation and cellular uptake.28 Nevertheless, adenosine
accumulation can lead to chronic inflammation and
diseases.10 Surprisingly, using millimolar concentrations
(1–5mM), we observed that exogenous adenosine alone
was able to induce NLRP3 inflammasome activation.
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Adenosine receptors which affinities to adenosine range
between 1 nM to 20 μM are probably desensitized and
not involved in response to adenosine 1–5mM. Indeed, this
adenosine receptor-independent effect was not mediated by
millimolar doses of the non-degradable adenosine analogue,
NECA, indicating that the inflammasome activation depends
on adenosine metabolism and/or transport. Here, we show for
the first time that exogenous adenosine at millimolar concen-
trations promoted NLRP3 expression and inflammasome
activation and mature IL-1β secretion through cellular uptake
and transformation into ATP by macrophages, leading to the
increase of intracellular ATP content, subsequent ATP release
and IL-1β secretion. Moreover, the functional activity of the
nucleotide transporter ENT2 present at the cell membrane
and of the intracellular adenosine kinase, which transforms
intracellular adenosine into ATP, was required. Indeed,
millimolar concentrations of adenosine were shown to
efficiently increase intracellular ATP contents in primary
lymphocytes and multiple cancer cell lines.28 In an attempt
to summarise our data, we propose a model presented in
Figure 9. As we showed very recently that the NLRP3
inflammasome is released as a particulate danger signal
and phagocytosed by surrounding macrophages, one can
imagine that adenosine uptake by these neighbouring cells
may amplify the inflammatory response.29 Our in vitro results
provide a new mechanism by which adenosine accumulation
in vivo may sustain inflammasome activation, leading to
chronic inflammatory diseases.30 Adenosine degradation in
inosine by ADA could be a good strategy to attenuate
adenosine-mediated inflammation via specific receptor signal-
ling and to avoid adenosine accumulation and cellular uptake.
To evaluate the role of adenosine in pulmonary inflammation
and the potential anti-inflammatory effect of degradation of
adenosine by ADA, we exposed mice to nano-SiO2 in the
presence of ADA. Our results indicate that adenosine
produced locally after nanoparticle exposure presents pro-
inflammatory effects and that irreversible degradation of
adenosine to inosine by ADA treatment reduced early
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Figure 8 Pulmonary inflammation upon instillation of nanoparticles is partially dependent on adenosine production. C57BL/6 mice were instilled with saline solution or nano-
TiO2 (5 mg/kg). Lung histology was performed 24 h after instillation to visualise aggregates of nanoparticles and inflammation in tissue (haematoxylin and eosin staining; original
magnification, × 1000; micrographs are representatives of 5 mice per group) (a). Simultaneously to the instillation of vehicle or nano-SiO2, mice were treated or not
intraperitoneally with adenosine deaminase (ADA, 5 U/mouse). Inflammation parameters were investigated at 6 h. Neutrophil counts (b) KC (c) and MMP-9 (d) contents were
measured in the BALF. Myeloperoxidase (MPO) level (e) and IL-1β secretion (f) in lung homogenates were measured. Data are representative of three independent experiments.
(*P≤0.05, **P≤0.01, ***P≤0.001)
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pulmonary inflammation. Several studies indicated that extra-
cellular adenosine can rise from baseline to high local
concentrations in chronic diseases, adenosine being pro-
inflammatory.8,10–16 Our study supports the idea that adeno-
sine can act as a pro-inflammatory mediator in certain
circumstances. Moreover, we demonstrate that depending
on its microenvironment concentration adenosine acts
through different mechanisms, in particular adenosine-
receptor signalling or adenosine cellular reuptake. Altogether,
this indicates that signalling through adenosine is finely tuned
and may be involved in both pro-inflammatory and anti-
inflammatory processes. Nanoparticles are known to exacer-
bate respiratory diseases such as asthma and COPD.31
Their toxicity or inflammatory effects depend on nanoparticle
shape and size and the amount of metal ion released.32
Cobalt-chromium nanoparticles were shown to induce human
fibroblast damages without crossing the plasma membrane,
through transmission of ATP via hemichannels and pannexin
channels and intercellular signalling.33 Nevertheless, the role
of adenosine was never described in nanoparticle-mediated
damage or inflammation.
In conclusion, after tissue injury, adenosinemay activate the
inflammasome throughmembrane receptor signalling. In case
of chronic inflammation, adenosine may accumulate and act
via its cellular uptake and conversion into intracellular ATP,
allowing amplifying and/or prolonging inflammasome activa-
tion. This may explain why sustained high adenosine levels
are pro-inflammatory. Our findings may provide new thera-
peutic approaches to control chronic inflammation by inhibiting
nucleotide receptors, nucleoside transporters and/or adeno-
sine kinase activation.
Methods
Reagents. Nano-SiO2 and nano-TiO2 were purchased from IoLiTec (Heilbronn,
Germany), and nano-ZnO is a gift from Dr. Amir Yazdi (Lausanne, Switzerland).
Nanoparticles were sonicated for 30 min and used at a concentration of 125–
500 μg/ml in vitro or at a concentration of 5 mg/kg in vivo, as mentioned. A740003 is
a gift from Dr. F. Rassendren (Montpellier, France). Adenosine deaminase (ADA)
(A5168), ADP, ADPβS, adenosine (Ado), apyrase grade VII (A6535), ARL67156,
ATPγS, ATP, carbenoxolone (Cbx), DPCPX, flufanemic acid (FFA), inosine (Ino),
MRS1523, MRS1754, MRS2395, MRS2578, periodate-oxidised ATP (oATP),
phorbol 12-myristate 13-acetate (PMA), SCH58261 and U73122 were from Sigma
(St. Quentin Fallavier, France); suramin was from VWR (Fontenay-sous-bois,
France); LPS (lipopolysaccharide from Escherichia coli, serotype 055:B5) was from
Invivogen (Toulouse, France); 2-APB, 5-Iodotubercidin, Forskolin, MRS2500,
NBMPR and Z-YVAD-fmk were from Tocris (Bristol, UK) and NECA and
SQ22536 were from Merck Millipore (Nottingham, UK).
Mice. C57BL/6 wild-type mice were bred in our animal facility (CNRS, Orleans).
The animals used were eight to ten weeks old, and they were kept in isolated and
ventilated cages. All animal experiments complied with the French Government’s
ethical and animal experiment regulations.
Lung inflammation model. Nano-SiO2 or nano-TiO2 in saline (5 mg/kg) or
vehicle alone was administered by intranasal instillation under light ketamine
(Imalgène 1000, 1.25 mg/ml) and xylazine (Rompun 0.1%) anaesthesia.
Bronchoalveolar lavage (BAL) and lung tissue were assayed after 6 h. The lungs
were homogenised in a solution containing 10 mM potassium phosphate and
0.1 mM EDTA (Sigma), centrifuged at 10 000 r.p.m. for 10 min and the supernatants
were stored at − 20 °C for further analysis. BAL was performed as previously
described.34 Differential cell counts were performed by counting an average of 250
cells on cytospin preparations (Shandon CytoSpin 3, Thermo Scientific, Illkirch,
Figure 9 Schematic diagram illustrating the specific cascade and signalling pathway in LPS-primed macrophages stimulated with nanoparticles. LPS priming induces
transcription of pro-IL-1β gene upon activation of the transcription factor NF-κB (1). Nanoparticle uptake (2) leads to the active release of intracellular ATP (3) through pannexin/
connexin hemichannels (4). This extracellular ATP (eATP) may activate ATP-gated P2X7 receptor (P2X7) to amplify ATP release in a P2X7-dependent way (5). ATP or its derived
catabolism products act through on other P1 or P2 (P2X and P2Y) purinergic receptors. In particular, ATP via P2Y2 and ADP through P2Y1 activate PLC-β, which promotes
NLRP3 inflammasome via modulation of cellular Ca2+ and K+ flux (6). Adenosine (Ado), another hydrolysed product of ATP, activates P1 receptors (A2A, A2B and A3) leading to
NLRP3 inflammasome activation (7). After NLRP3 receptor activation via signalling through multiple purinergic receptors, NLRP3 inflammasome builds up and matures pro-IL-1β
(9) into IL-1β, which is secreted by macrophages (10). In case of extracellular Ado accumulation, equilibrative nucleotide transporters (ENTs) regulate adenosine through its
cellular reuptake, which may be inhibited by the ENT inhibitors MBMPR and/or 5-Iodotubercidin (a). Metabolisation of intracellular Ado into ATP by adenosine kinase (AK) renews
ATP stock (b) and may be inhibited by the AK inhibitor 5-Iodotubercidin. Increased intracellular ATP contents may lead to ATP release (4), NLRP3 inflammasome activation (9) and
IL-1β secretion (10)
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France) after May-Grünwald-Giemsa staining (Diff Quick, Medion Diagnostics,
Düdingen, Switzerland) according to the manufacturer’s instructions. After BAL and
lung perfusion, the large lobe was fixed and 3-μm sections were stained as
described previously.35
ELISA. IL-1β, KC, MMP-9 and MPO levels were determined using ELISA assay
kits (Mouse or human DuoSet, R&D system, Minneapolis, MN, USA) according to
the manufacturer’s instructions.
THP1 culture and stimulation. Monocyte/macrophage THP1 cells are a gift
from Dr. Amir Yazdi (Lausanne, Switzerland) and cultured in RMPI Medium 1640
(Gibco, Illkirch, France) with 10% fetal calf serum (Hyclone, Cramlington, UK) and
penicillin/streptomycin (100 U/ml, Invitrogen). For experiments, THP1 were
differentiated for 3 h with 0.5 μM PMA, washed and plated overnight (2 × 105
cells/well). Cells were stimulated for indicated times, the supernatant was collected
for immediate ATP measurement and/or stored for further IL-1β quantification.
Cell death was monitored by MTT using a standard protocol. Thiazollyl blue
tetrazolium bromide (Sigma) solution was added onto the cells after supernatant
collection and incubated for 2 h at 37 °C, and a 10% SDS acetic acid solution is then
added. MTT reduction to formazan was quantified by an absorbance microplate
reader (EL800, BioTek, Colmar, France) at 610nm (KC4 software). Apoptotic and
necrotic cell death of primed THP1 cells was also monitored using AnnexinV/PI
staining (eBioscience, San Diego, CA, USA). Cells were gently detached using
repeated aspiration and expulsion of cold PBS. After centrifugation, cells were
resuspended in annexin V binding buffer and stained for 20 min with Annexin V and
propidium iodide. Data were collected on a BD FACSCanto and analysed using
Flowjo software (Tree Star, OR, USA).
Sh RNA THP1. THP1 stably expressing short hairpin RNA (shRNA) against
lamin (‘sh CTL’), ASC or NLRP3 are kind gifts from Dr. Fabio Martinon (Lausanne,
Switzerland) and were obtained as previously described (Pétrilli et al., 2007).
shRNA THP1 cells were cultured in RPMI Medium 1640 (Gibco) with 10% fetal calf
serum (Hyclone) and 4 μg/ml puromycin (Gibco). Cell priming and stimulation are
the same as previously described for untransfected THP1 cells.
ATP measurement. Extracellular ATP in cell-free medium supernatant was
quantified using ATP Lite one step kit (Perkin Elmer, Courtaboeuf, France)
according to the manufacturer’s instructions, and the luminescence produced was
measured (Mithras, Mikrowin 2000 software, Berthold Technologies, Thoiry, France).
BMDM culture and stimulation. Primary BMDMs were obtained from
femoral bone marrow as described.36 In brief, cells from femurs of C57BL/6 mice
were isolated and cultured at 106 cells/ml for 7 days in Dulbecco’s minimal essential
medium (DMEM, Sigma) supplemented with 20% horse serum and 30% L929 cell-
conditioned medium as a source of M-CSF. Three days after washing and culturing
in fresh medium, the cell preparation contained a homogeneous population of
495% macrophages (Müller et al.36). The BMDMs were plated in 96-well
microculture plates (2.105cells/well) and stimulated with 100 ng/ml LPS during 3 h to
induce pro-IL-1β production. Particles were applied for 6 h and cell supernatants
were collected after 6 h and stored for further analysis. The absence of cytotoxicity
of the different stimuli used was verified by MTT assay using the standard protocol.
Quantitative RT-PCR. BMDM or THP1 cells were plated in six-well
microculture plates (at 5 × 106 cells/well), stimulated during 3 h with LPS or PMA,
respectively, and were washed and stimulated with particles for 4 or 6 h. RNA was
extracted using the RNeasy Mini Kit (Qiagen, Courtaboeuf, France) and particles
were removed by centrifugation (10 000 g, 10 min, 4 °C). All primers were
synthesised (Qiagen). The expression levels of A1, A2A, A2B, A3, P2X7, P2Y1,
P2Y2, P2Y4, P2Y6, P2Y12 and P2Y13 receptor mRNAs, relative to housekeeping
18S mRNA, and expression of ENT1 and ENT2 transporter mRNAs, relative to
housekeeping β2m mRNA, were analysed using Quantitect gene expression assays
(Qiagen). Reverse transcription was performed by SuperScript III Reverse
Transcriptase (Fisher Invitrogen) according to the manufacturer’s instructions for
amplification. RT-PCR was performed starting from 500 ng of total RNA using a
Stratagene Mx3005P real-time PCR system (Agilent Technologies, Massy, France).
For all experiments, biological quadruplicates and technical triplicates were
performed.
Immunoblotting. BMDM cells were plated in 12-well microculture plates (at
3 × 106 cells/well), stimulated with LPS during 3 h and were washed and stimulated
with particles during 6 h. Supernatants were collected and stored at − 20 °C for
further analysis. BMDMs were washed with cold PBS and scraped in lysis buffer
solution (150 mM NaCl, 10 mM Tris pH 8, 1 mM EDTA, 0.2% SDS and 1% Nonidet
P-40) supplemented with a protease inhibitor cocktail (1%) and pefabloc (0.1 mg/ml)
(Roche Applied Science, Meylan, France). Lysis extracts and supernatants were
collected and protein content was measured (DC protein assay, Bio-Rad, Munich,
Germany). Proteins were denatured by boiling (95 °C, 5 min), separated by SDS–
PAGE and transferred to nitrocellulose membranes. The membranes were
immunoblotted with a primary goat anti-IL-1β antibody (Sigma Aldrich) or rabbit
anti-caspase-1 p10 (Santa Cruz Biotechnology) and proteins were detected with
appropriate secondary antibody followed by enhanced chemiluminescence (ECL,
Fisher, Illkirch, France).
Statistical analysis. Statistical evaluation of differences between the
experimental groups was determined by ANOVA followed by Bonferroni's test
using the Prism 5.0 software (GraphPad). P-values o0.05 were considered
statistically significant.
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